References
- McDermott JD, Bowles DW. Epidemiology of head and neck squamous cell carcinomas: impact on staging and prevention strategies. Curr Treat Options Oncol 2019; 20: 43. doi: 10.1007/s11864-019-0650-5
- Widmann G, Henninger B, Kremser C, Jaschke W. MRI sequences in head & neck radiology - state of the art. Rofo 2017; 189: 413-22. doi: 10.1055/s-0043-103280
- Padhani AR, Liu G, Koh DM, Chenevert TL, Thoeny HC, Takahara T, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009; 11: 102-25. doi: 10.1593/neo.81328
- Surov A, Meyer HJ, Wienke A. Can imaging parameters provide information regarding histopathology in head and neck squamous cell carcinoma? A meta-analysis. Transl Oncol 2018; 11: 498-503. doi: 10.1016/j.tranon.2018.02.004
- Surov A, Meyer HJ, Wienke A. Correlation between apparent diffusion coefficient (ADC) and cellularity is different in several tumors: a meta-analysis. Oncotarget 2017; 8: 59492-9. doi: 10.18632/oncotarget.17752
- Hauge A, Wegner CS, Gaustad JV, Simonsen TG, Andersen LMK, Rofstad EK. Diffusion-weighted MRI-derived ADC values reflect collagen I content in PDX models of uterine cervical cancer. Oncotarget 2017; 8: 105682-91. doi: 10.18632/oncotarget.22388
- Swartz JE, Driessen JP, van Kempen PMW, de Bree R, Janssen LM, Pameijer FA, et al. Influence of tumor and microenvironment characteristics on diffusion-weighted imaging in oropharyngeal carcinoma: a pilot study. Oral Oncol 2018; 77: 9-15. doi: 10.1016/j.oraloncology.2017.12.001
- Meyer HJ, Leifels L, Hamerla G, Höhn AK, Surov A. ADC-histogram analysis in head and neck squamous cell carcinoma. Associations with different histopathological features including expression of EGFR, VEGF, HIF-1α, Her 2 and p53. A preliminary study. Magn Reson Imaging 2018; 54: 214-7. doi: 10.1016/j.mri.2018.07.013
- Surov A. Meyer HJ, Winter K, Richter C, Hoehn AK. Histogram analysis parameters of apparent diffusion coefficient reflect tumor cellularity and proliferation activity in head and neck squamous cell carcinoma. Oncotarget 2018; 9: 23599-607. doi: 10.18632/oncotarget.25284
- Driessen JP, van Kempen PM, van der Heijden GJ, Philippens ME, Pameijer FA, Stegeman I, et al. Diffusion-weighted imaging in head and neck squamous cell carcinomas: a systematic review. Head Neck 2015; 37: 440-8. doi: 10.1002/hed.23575
- Koontz NA, Wiggins RH 3rd. Differentiation of benign and malignant head and neck lesions with diffusion tensor imaging and DWI. AJR Am J Roentgenol 2017; 208: 1110-5. doi: 10.2214/AJR.16.16486
- Surov A. Meyer HJ, Wienke A. Apparent diffusion coefficient for distinguishing between malignant and benign lesions in the head and neck region: a systematic review and meta-analysis. Front Oncol 2020; 9: 1362. doi: 10.3389/fonc.2019.01362
- King AD, Chow KK, Yu KH, Mo FK, Yeung DK, Yuan J, et al. Head and neck squamous cell carcinoma: diagnostic performance of diffusion-weighted MR imaging for the prediction of treatment response. Radiology 2013; 266: 531-8. doi: 10.1148/radiol.12120167
- Law BK, King AD, Bhatia KS, Ahuja AT, Kam MK, Ma BB, et al. Diffusion-weighted imaging of nasopharyngeal carcinoma: can pretreatment DWI predict local failure based on long-term outcome? AJNR Am J Neuroradiol 2016; 37: 1706-12. doi: 10.3174/ajnr.A4792.
- Matoba M, Tuji H, Shimode Y, Toyoda I, Kuginuki Y, Miwa K, et al. Fractional change in apparent diffusion coefficient as an imaging biomarker for predicting treatment response in head and neck cancer treated with chemoradiotherapy. AJNR Am J Neuroradiol 2014; 35: 379-85. doi: 10.3174/ajnr.A3706
- Schneider S, Kadletz L, Wiebringhaus R, Kenner L, Selzer E, Füreder T, et al. PD-1 and PD-L1 expression in HNSCC primary cancer and related lymph node metastasis - impact on clinical outcome. Histopathology 2018; 73: 573-84. doi: 10.1111/his.13646
- Leemans CR, Snijders PJF, Brakenhoff RH. The molecular landscape of head and neck cancer. Nat Rev Cancer 2018; 18: 269-82. doi: 10.1038/nrc.2018.11
- Tang H, Zhou X, Ye Y, Zhou Y, Wu C, Xu Y. The different role of PD-L1 in head and neck squamous cell carcinomas: a meta-analysis. Pathol Res Pract 2020; 216: 152768. doi: 10.1016/j.prp.2019.152768
- Yang WF, Wong MCM, Thomson PJ, Li KY, Su YX. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: a systematic review and meta-analysis. Oral Oncol 2018; 86: 81-90. doi: 10.1016/j.oraloncology.2018.09.016
- Lin YM, Sung WW, Hsieh MJ,Tsai SC, Lai HW, Yang SM, et al. High PD-L1 expression correlates with metastasis and poor prognosis in oral squamous cell carcinoma. PLoS One 2015; 10: e0142656. doi: 10.1371/journal.pone.0142656.
- Surov A, Meyer HJ, Wienke A. Associations between apparent diffusion coefficient (ADC) and KI 67 in different tumors: a meta-analysis. Part 1: ADCmean.Oncotarget 2017; 8: 75434-44. doi: 10.18632/oncotarget.20406
- Just N. Improving tumour heterogeneity MRI assessment with histograms. Br J Cancer 2014; 111: 2205-13. doi: 10.1038/bjc.2014.512
- de Perrot T, Lenoir V, Domingo Ayllón M, Dulguerov N, Pusztaszeri M, Becker M. Apparent diffusion coefficient histograms of human papillomavirus-positive and human papillomavirus-negative head and neck squamous cell carcinoma: assessment of tumor heterogeneity and comparison with histopathology. AJNR Am J Neuroradiol 2017; 38: 2153-60. doi: 10.3174/ajnr.A5370.
- Rasmussen JH, Olin A, Lelkaitis G, Hansen AE, Andersen FL, Johannesen HH, et al. Does multiparametric imaging with 18F-FDG-PET/MRI capture spatial variation in immunohistochemical cancer biomarkers in head and neck squamous cell carcinoma? Br J Cancer 2020; 123: 46-53. doi: 10.1038/s41416-020-0876-9
- Choi JW, Lee D, Hyun SH, Han M, Kim JH, Lee SJ. Intratumoural heterogeneity measured using FDG PET and MRI is associated with tumour-stroma ratio and clinical outcome in head and neck squamous cell carcinoma. Clin Radiol 2017; 72: 482-9. doi: 10.1016/j.crad.2017.01.019
- Chow LQM, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol 2016; 34: 3838-45. doi: 10.1200/JCO.2016.68.1478.
- Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016; 375: 1856-67. doi: 10.1056/NEJMoa1602252
- Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 2016; 17: 956-65. doi: 10.1016/S1470-2045(16)30066-3
- Ledgerwood LG, Kumar D, Eterovic AK, Wick J, Chen K, Zhao H, et al. The degree of intratumor mutational heterogeneity varies by primary tumor sub-site. Oncotarget 2016; 7: 27185-98. doi: 10.18632/oncotarget.8448.
- Lyford-Pike S, Peng S, Young GD, Taube JM, Westra WH, Akpeng B, et al. Evidence for a role of the PD-1: PD-L1 pathway in immune resistance of human papillomavirus -associated head and neck squamous cell carcinoma. Cancer Res 2013; 73: 1733-41. doi: 10.1158/0008-5472.CAN-12-2384.
- Meyer HJ, Höhn A, Surov A. Histogram analysis of ADC in rectal cancer: associations with different histopathological findings including expression of EGFR, Hif1-alpha, VEGF, p53, PD1, and KI 67. A preliminary study. Oncotarget 2018; 9: 18510-7. doi: 10.18632/oncotarget.24905